Our news

Symeres welcomes Dr. Henning Steinhagen as Chief Executive Officer, bringing over 25 years of leadership experience across pharma, biotech and the CRO/CDMO sector. His appointment marks an exciting step forward as Symeres continues to strengthen its integrated “One Symeres” platform and support drug discovery and development from concept to clinic.

Symeres has partnered with Ambagon Therapeutics to evaluate molecular glues for colorectal cancer, combining translational research and in vitro studies to support early-stage development.

Symeres has achieved ISO27001 certification, strengthening data security and compliance to protect client IP and support trusted collaboration in drug development.

Exemplify BioPharma CSO Paul O’Shea shares his perspective on the key drug development trends for 2026, including AI-driven decision-making and drug repurposing strategies.

Symeres has welcomed Jurgen Berendsen back as Chief Financial Officer to support the company’s next phase of growth, operational integration, and financial resilience.

Nijmegen, Netherlands – 17.12.25 – Symeres, a leading contract research, development, and manufacturing organisation (CRDMO), has received its first approval from the Science Based Targets initiative (SBTi) for its greenhouse gas (GHG) emissions reduction targets. This marks a major milestone in Symeres’ environmental strategy and affirms its commitment to building a more sustainable, low-carbon future. […]

With more than 25 years of international experience in the pharmaceutical, medical device, and services sectors, Gabriella brings a proven track record in operational performance, lean methodologies, and global transformation programs.

DGr Pharma specializes in preclinical and clinical regulatory strategy and consultancy for biotech and pharmaceutical partners working in early drug development. Its core services include chemical-pharmaceutical, non-clinical and clinical development planning, quality assurance, and regulatory submissions. DGr Pharma has deep expertise in small and large molecules including antibodies, ADCs, and oligonucleotides.

San Francisco, May 29, 2025 – Yoneda Labs, a leader in computational tools for reaction optimization, has successfully collaborated with Symeres, a leading transatlantic, small molecule contract research and manufacturing organization. The aim was to optimize transition metal catalyzed cross-coupling reactions to improve reaction yield and efficiency utilizing Yoneda Labs’ cutting-edge software.

The new production lines D1 and D2 were launched for the first time in May 2024 at the Prague site. The first batch of 11 kg of API was produced in the following weeks, and the tremendous efforts of the many people involved in planning the entire production line have finally paid off. Since the production line was launched, all equipment has been continuously utilized.

Nuclear Magnetic Resonance (NMR) Spectroscopy is a powerful analytical tool well known to all organic chemists and to anyone that works in pharmaceuticals. By placing a sample dissolved in deuterated solvent into a strong magnetic field (roughly 4000x the strength of Earth’s magnetic field) and pulsing it with radio frequencies, the chemist is given an enormous amount of information from the identity and placement of functional groups to relative stereochemistry of diastereomers. Recently, Exemplify added NMR to our expanding list of capabilities.

Symeres announces the evolution of its leadership team ahead of the company’s next phase of development. After nearly three decades at the helm, Symeres’ co-founders, Dr. Eelco Ebbers (CEO) and Dr. Frank Leemhuis (Head of Corporate Development), have decided to step back from their current executive roles.